NUVB

Nuvation Bio Inc.

Fundamental data last updated:November 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

United States

Next Earnings Date

Pending Announcement

Business Summary

Nuvation Bio Inc. operates within the biotechnology space, focusing on innovative cancer therapies. Its business model revolves around developing proprietary treatments, aiming to secure patents that provide a competitive edge. By targeting unmet medical needs, the company seeks to establish a strong foothold in niche markets. However, its moat relies heavily on successful clinical trials and regulatory approvals, which are inherently risky and capital-intensive.

 


Analyze NUVB on TradingView

VALUATION

P/E

-10.56

Market Cap ($M USD)

$1.61B

Forward P/E

8.03

PEG

0.34

PRICE TO SALES

9.46

PRICE TO BOOK

6.31

EV / EBITDA

-12.60

5-Year Average P/E

Free Cash Flow Yield

-7.52%

DCF Value

$3.08

Graham Number

N/A

Price to FCF

-13.29

EV to FCF

-13.24

Earnings Yield

-9.36%

FCF Yield

-7.52%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.43

Next Year EPS Growth Estimate

-$0.40

Next Year Revenue Growth Estimate

$194.50M

Return on Equity (ROE)

-49.73%

FREE CASH FLOW

Operating Margin

-81.00%

Debt-to-Equity

0.99

Piotroski F-Score

3

Altman Z-Score

0.45

Return on Invested Capital (ROIC)

-20.68%

Current Ratio

8.37

Quick Ratio

8.14

Net Debt to EBITDA

0.05

Interest Coverage

-5.16

Gross Profit margin

93.94%

FCF PER SHARE

$-0.35

REVENUE PER SHARE

$0.49

Analyze NUVB on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have mispriced Nuvation Bio Inc., as recent pricing indicated it traded above its DCF value. The Forward P/E of 8.03 suggests optimism about future earnings, yet the negative Earnings Yield and Altman Z-score of 0.45 raise red flags about financial stability. With a Price/Book ratio of 6.31, the stock appears overvalued relative to its book value, hinting at speculative pricing. Despite a consensus “Buy” rating, the company’s negative ROIC and operating margin suggest inefficiencies in capital deployment and operational execution.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Nuvation Bio is well-positioned to leverage advancements in AI for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with tech-driven shifts, potentially enhancing R&D efficiency. However, the rapid pace of technological change demands agile adaptation to maintain competitiveness.

The Bull Case

For the value-driven investor, Nuvation Bio offers intriguing potential. Despite a negative ROIC of -20.68%, the company's robust Current Ratio of 8.37 indicates strong liquidity, providing a buffer against short-term liabilities. The Piotroski F-Score of 3 suggests some financial distress, yet the massive projected sales growth could signal future profitability. With a Forward PEG of 0.34, the stock is attractively priced for growth, offering a compelling entry point for those betting on its turnaround.

The Bear Case

Nuvation Bio's structural weaknesses are glaring. The negative Price to FCF and EV to EBITDA ratios highlight severe cash flow issues, while the Price/Sales ratio of 9.46 suggests the stock is priced for perfection without the earnings to back it up. The company's operating margin of -81% underscores its struggle to convert revenue into profit, raising concerns about its long-term viability. Furthermore, trading significantly above its DCF value, the stock appears technically overextended, posing a risk of correction.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$20.50

Institutional Ownership %

1-Year Beta

1.62

Insider Buying % (6 Mo)

Distance to 52-Week High

112.42%

Distance to 52-Week Low

14.60%

EARNINGS SURPRISE %

-5.89%

50-DAY SMA

$5.73

200-DAY SMA

$5.41

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.